Targeted therapeutic options in early and metastatic NSCLC-overview

Targeted therapeutic options in early and metastatic NSCLC-overview

The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therap...

Full description

Bibliographic Details
Main Authors:	Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Pathology and Oncology Research
Subjects:	NSCLC driver oncogenes targeted therapy central nervous system efficacy molecular testing
Online Access:	https://www.por-journal.com/articles/10.3389/pore.2024.1611715/full

Similar Items

Capmatinib-induced interstitial lung disease: A case report
by: Kinan El Husseini, et al.
Published: (2020-12-01)

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
by: Umberto Malapelle, et al.
Published: (2023-06-01)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
by: Antonio Rossi, et al.
Published: (2022-02-01)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
by: Serena Badellino, et al.
Published: (2022-03-01)

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
by: Francesca Jacobs, et al.
Published: (2021-12-01)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
by: Fei-fei Gu, et al.
Published: (2016-08-01)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations
by: Yuji Uehara, et al.
Published: (2022-06-01)

Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation
by: Mizuki Takahashi, et al.
Published: (2023-04-01)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
by: Yijia Du, et al.
Published: (2022-12-01)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
by: Jinfeng Cui, et al.
Published: (2022-05-01)

The oncogenic role and regulatory mechanism of PGK1 in human non-small cell lung cancer
by: Tian Tian, et al.
Published: (2024-01-01)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
by: Alessandro Inno, et al.
Published: (2023-06-01)

Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers
by: Roberto Chiarle, et al.
Published: (2023-11-01)

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
by: Elisa De Carlo, et al.
Published: (2022-06-01)

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
by: Weijie Ma, et al.
Published: (2021-09-01)

Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients
by: Elba Marin, et al.
Published: (2020-04-01)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
by: Eleni Zografos, et al.
Published: (2022-10-01)

Establishment of a Temperature-Sensitive Model of Oncogene-Induced Senescence in Angiosarcoma Cells
by: Adilson da Costa, et al.
Published: (2020-02-01)

Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
by: John Inge Johnsen, et al.
Published: (2019-01-01)

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature
by: Shannon S. Zhang, MD, et al.
Published: (2022-09-01)

Diagnostics for Targeted NSCLC Therapy
by: Verena Schildgen, et al.
Published: (2017-11-01)

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
by: David J. Benjamin, MD, et al.
Published: (2022-12-01)

Non-Mutational Key Features in the Biology of Thymomas
by: Stefan Küffer, et al.
Published: (2024-02-01)

Role of Transcription Factor BEND3 and Its Potential Effect on Cancer Progression
by: Sarah Naiyer, et al.
Published: (2023-07-01)

ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors
by: Cristina Terlizzi, et al.
Published: (2023-11-01)

Immunotherapy in NSCLC Patients with Brain Metastases
by: Silvia Buriolla, et al.
Published: (2022-06-01)

Diagnostic and Therapeutic Strategy Updates of Rare Oncogenic Mutations in Chinese Society of Clinical Oncology Guidelines on Diagnosis and Treatment of Non-small Cell Lung Cancer (2023 Edition)
by: LI Yingge, et al.
Published: (2023-12-01)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <em>BRAF</em> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
by: Jean-Bernard Auliac, et al.
Published: (2020-12-01)

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
by: Calogera Claudia Spagnolo, et al.
Published: (2023-06-01)

Precision Surgery in NSCLC
by: Giorgio Cannone, et al.
Published: (2023-03-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-04-01)

TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01)

Updated Prognostic Factors in Localized NSCLC
by: Simon Garinet, et al.
Published: (2022-03-01)

Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
by: Laetitia Seguin, et al.
Published: (2022-03-01)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
by: D. Gwyn Bebb, et al.
Published: (2021-01-01)

CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features
by: Vinay K. Kartha, et al.
Published: (2019-02-01)

To Become or Not to Become Tumorigenic: Subventricular Zone Versus Hippocampal Neural Stem Cells
by: Ángela Fontán-Lozano, et al.
Published: (2020-11-01)

Mechanisms of Resistance to KRAS<sup>G12C</sup> Inhibitors
by: Victoria Dunnett-Kane, et al.
Published: (2021-01-01)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
by: Huijuan Wang, et al.
Published: (2020-01-01)

The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
by: Alessandra Bearz, et al.
Published: (2022-06-01)